PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18991162-8	2009	Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of alpha-SMA protein expression and pro-fibrosis factors TGF-beta1 and CTGF.	Rosiglitazone	0-13	glutamic pyruvic transaminase, soluble	Mus musculus	42-45	
28357820-8	2017	Rosiglitazone pre-treatment prevented the increases in ALT (and AST), soluble E-selectin concentration, red blood cells and platelet counts.	Rosiglitazone	0-13	glutamic pyruvic transaminase, soluble	Mus musculus	55-58	
28652653-11	2017	In contrast, the combination of serelaxin and rosiglitazone resulted in significantly improved ALT levels (P < 0.05).	Rosiglitazone	46-59	glutamic pyruvic transaminase, soluble	Mus musculus	95-98	
18846339-10	2008	Contrarily, the levels of TNF-alpha and ALT in portal vein were markedly down-regulated in rosiglitazone group as compared with vehicle group at every time point in mouse partial hepatic IRI model.	Rosiglitazone	91-104	glutamic pyruvic transaminase, soluble	Mus musculus	40-43	
35340872-8	2022	The results showed that RSG could reverse the CCl4-mediated decrease in the levels of SOD, CAT and GSH, and increase in the levels of ALT, AST, MDA, NO and ROS.	Rosiglitazone	24-27	glutamic pyruvic transaminase, soluble	Mus musculus	134-137	
24898700-7	2014	Treatment by rosiglitazone sustained PGC-1alpha and Mfn2 expression both in IR livers, and L02 cells treated with TNF-alpha as indicated by increased hepatic mitochondrial integrity and ATP production, reduced ROS and ALT activity as well as decreased cell apoptosis.	Rosiglitazone	13-26	glutamic pyruvic transaminase, soluble	Mus musculus	218-221